Dr. Walther received his MD-PhD as a Duke MSTP trainee; his urologic residency at UCLA; an American Cancer Society junior faculty fellowship at Duke; and subsequently an MBA from Duke’s Fuqua School of Business (health care management). His lab research interests have been: 1) Developmental GU onco-therapeutics using human xenograft-supported GU tumors (primarily bladder) 2) the genomic elucidation of the role of oncogenic HPV genotypes with lower GU cancers (bladder, penis, and urethra). He served as Chair, GU Surgery Subcommittee of the NIH-funded cooperative study group-CALGB. He was the Site PI at Duke for the first NIH-sponsored multi-institutional study of immune-therapeutics of renal cancer using high-dose interleukin-2, and served as PI of a R21-funded grant to initiate an institutional research program in Prostate Cancer (seeding startup seed research grants). He also was PI of a VA-based epidemiologic effort (with Community Medicine) in the study of relevant black vs. white genomic differences associated with Prostate Cancer occurrence. Finally, he served on the Study Committee of a 7 year, 35000+ man NIH-sponsored nutritional intervention Prostate Cancer prevention study (Vitamin E vs. Selenium -SELECT). Dr. Walther serves on the KURe Advisory Committee.